MedTrace Logo

Tofacitinib in Recurrent GBM Patients

NCT05326464 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.

Conditions

Interventions

DRUG

Tofacitinib 10mg

10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.

DRUG

Temozolomide

Temozolomide 150mg/m2 - 200mg/m2 on days 1-5

DRUG

Lomustine

Lomustine 90mg/m2 on day 1

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Michael Youssef, MD · Assistant Professor

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-07
Primary Completion
2025-02-18
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326464 on ClinicalTrials.gov